The Use of Disease-Specific Health-Related Quality of Life (HRQOL)/ Patient Reported Outcomes (PROS) Scales in Rare Inflammatory Conditions (RICS)

Author(s)

Grieve S1, Patel V1, Tzonev C1, Richard ME1, Islam S2, Thakur D1
1Cytel, Inc, Montreal, QC, Canada, 2Cytel, Inc, Ottawa, ON, Canada

Presentation Documents

OBJECTIVES: HRQoL/PRO endpoints are heavily weighed by patients and payer bodies. Disease-specific scales may be less available and not validated in rare conditions, making the accurate determination of HRQoL in these patients difficult. Our objective was to understand how frequently disease-specific scales are used in RICs trials and how HRQoL outcomes are incorporated in National Institute for Health and Care Excellence (NICE) health technology assessments (HTAs) in these populations.

METHODS:

For 24 identified RICs, a review of ClinicalTrials.gov from the last five years was undertaken using indication names and “quality of life” search terms. Data regarding the HRQoL/PRO scales used and the frequency of disease-specific HRQoL scales were extracted. HTAs from NICE were reviewed for each indication to understand if and how payers incorporate HRQoL assessments in their submissions and comments on use of scales were collected.

RESULTS: No clinical trials reporting HRQoL were identified for two RICs (hereditary chronic cholestasis, cryopyrin fevers). A total of 839 trials in 22 RICs were identified and reviewed. HRQoL/PRO scales were reported in 689 trials (82.1%) and the majority (58.9%) of clinical trials listed a least one disease-specific scale as a secondary outcome. Conditions that frequently used disease-specific scales were hereditary angioedema (100%), primary biliary cholangitis (87%), myasthenia gravis (81%) and multiple sclerosis (71%). Despite the relatively high frequency of disease-specific scales seen in clinical trials, of 25 NICE appraisals, only 10 submissions included disease-specific scales; 2 mapped them to EQ-5D. Disease-specific scores were not translated into utilities in 5 submissions due to absence of validated mapping methods and/or evaluators’ concerns with the validity of results.

CONCLUSIONS:

Patients with RICs have poor HRQoL; its assessment is crucial for designing a patient-centric approach to assessment of outcomes in clinical trials. While disease-specific scales are commonly used in clinical trials, their incorporation into HTA submissions is limited.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)

Code

MSR26

Topic

Methodological & Statistical Research, Patient-Centered Research, Study Approaches

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes, PRO & Related Methods, Registries

Disease

SDC: Gastrointestinal Disorders, SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal), SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×